Yahoo
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedica
Yahoo
Oragenics (OGEN) said Tuesday it priced a public offering of up to 800,000 shares of series H conver
Yahoo
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 865,000 Class A Units with each Class A Unit cons
Yahoo
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transfor
Yahoo
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA
Yahoo
FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company’s common stock, par value $0.00001, which will become effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. The company’s common stock will continue to trade under its c
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NOMD | -<0.01% | $2.67B | +4.07% | 3.70% |
| NEE | -0.01% | $153.66B | -0.08% | 2.93% |
| JBSS | -0.03% | $789.96M | -28.46% | 1.27% |
| RVLV | 0.04% | $1.55B | +34.34% | 0.00% |
| LUMN | 0.05% | $4.63B | +288.79% | 0.00% |
| CVM | 0.05% | $20.33M | -89.73% | 0.00% |
| CF | 0.05% | $15.51B | +36.12% | 2.09% |
| CHKP | 0.06% | $23.98B | +30.15% | 0.00% |
| TBRG | -0.07% | $344.94M | +116.20% | 0.00% |
| PKX | 0.07% | $17.38B | -19.02% | 2.32% |
| SM | 0.08% | $3.25B | -37.13% | 2.76% |
| CCL | -0.08% | $38.19B | +60.60% | 0.00% |
| CUK | 0.09% | $3.88B | +60.33% | 0.00% |
| GEF | 0.09% | $3.92B | +13.12% | 3.22% |
| JBLU | 0.09% | $1.62B | -22.71% | 0.00% |
| ALK | -0.13% | $6.58B | +42.92% | 0.00% |
| PRM | -0.13% | $2.41B | +100.74% | 0.00% |
| OR | -0.14% | $5.02B | +60.19% | 0.71% |
| CRMD | -0.14% | $871.57M | +138.49% | 0.00% |
| BAP | 0.15% | $17.78B | +34.49% | 4.95% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 24.00% | $1.03B | 0.75% |
| PINK | 23.90% | $130.30M | 0.5% |
| PTH | 23.65% | $96.25M | 0.6% |
| GNOM | 22.40% | $46.47M | 0.5% |
| XBI | 22.21% | $4.81B | 0.35% |
| BATT | 22.14% | $62.34M | 0.59% |
| IBB | 21.72% | $5.37B | 0.45% |
| FHLC | 20.85% | $2.43B | 0.084% |
| EWD | 20.72% | $376.15M | 0.54% |
| VHT | 20.42% | $15.34B | 0.09% |
| PGJ | 20.10% | $141.15M | 0.67% |
| PBE | 20.08% | $226.91M | 0.58% |
| IXJ | 19.78% | $3.75B | 0.41% |
| ERTH | 19.57% | $137.44M | 0.67% |
| IDRV | 19.53% | $152.69M | 0.47% |
| IBHF | 19.30% | $866.52M | 0.35% |
| PBW | 19.26% | $294.50M | 0.65% |
| CHIQ | 19.22% | $231.20M | 0.65% |
| IYH | 19.21% | $2.72B | 0.39% |
| XLV | 19.05% | $34.17B | 0.09% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FTGC | 0.05% | $2.44B | 0.98% |
| SGOL | 0.05% | $5.21B | 0.17% |
| JAAA | -0.07% | $22.20B | 0.2% |
| GLDM | -0.11% | $15.88B | 0.1% |
| BAR | -0.11% | $1.11B | 0.1749% |
| BSCQ | 0.19% | $4.25B | 0.1% |
| IAU | 0.23% | $47.13B | 0.25% |
| DEFI | 0.24% | $14.78M | 0.94% |
| OUNZ | 0.28% | $1.73B | 0.25% |
| TBIL | -0.28% | $5.76B | 0.15% |
| BTCW | 0.30% | $168.52M | 0.3% |
| ARGT | 0.30% | $1.02B | 0.59% |
| ARKB | 0.31% | $5.25B | 0.21% |
| GLD | 0.33% | $100.92B | 0.4% |
| VRIG | 0.36% | $1.21B | 0.3% |
| GBTC | 0.37% | $20.03B | 1.5% |
| KMLM | 0.37% | $187.82M | 0.9% |
| FBTC | 0.41% | $22.25B | 0.25% |
| BITO | 0.42% | $2.61B | 0.95% |
| BITB | 0.43% | $4.36B | 0.2% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -12.25% | $31.06M | 0.65% |
| BTAL | -12.13% | $315.93M | 1.43% |
| VIXY | -11.77% | $184.73M | 0.85% |
| TAIL | -9.64% | $94.86M | 0.59% |
| UUP | -9.53% | $196.45M | 0.77% |
| UGA | -9.30% | $76.33M | 0.97% |
| USDU | -8.59% | $129.80M | 0.5% |
| XHLF | -7.50% | $1.73B | 0.03% |
| DBE | -6.83% | $54.61M | 0.77% |
| CTA | -6.63% | $1.08B | 0.76% |
| DBO | -6.32% | $233.09M | 0.77% |
| USO | -6.24% | $1.06B | 0.6% |
| UNG | -6.20% | $375.27M | 1.06% |
| BNO | -6.12% | $110.71M | 1% |
| PALL | -6.06% | $521.82M | 0.6% |
| BIL | -5.62% | $41.93B | 0.1356% |
| BSCP | -5.57% | $3.25B | 0.1% |
| BILS | -5.53% | $3.80B | 0.1356% |
| STPZ | -4.85% | $443.27M | 0.2% |
| FLIA | -4.51% | $706.55M | 0.25% |
Current Value
$4.961 Year Return
Current Value
$4.961 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SFIX | -15.82% | $533.69M | -14.08% | 0.00% |
| LFVN | -14.93% | $155.72M | +105.82% | 1.34% |
| XGN | -11.71% | $153.02M | +261.76% | 0.00% |
| VITL | -10.73% | $1.73B | -11.75% | 0.00% |
| CALM | -9.34% | $5.37B | +59.42% | 6.69% |
| RPTX | -9.09% | $66.91M | -56.06% | 0.00% |
| FDP | -8.29% | $1.61B | +52.20% | 3.28% |
| MDLZ | -8.01% | $86.95B | +2.80% | 2.82% |
| MUX | -7.82% | $574.43M | +3.30% | 0.00% |
| FATBB | -7.69% | $47.76M | -9.82% | 10.45% |
| PBF | -7.55% | $3.23B | -31.57% | 3.88% |
| IMDX | -7.26% | $82.65M | -8.25% | 0.00% |
| PRMB | -7.23% | $11.49B | +48.80% | 1.26% |
| COKE | -7.13% | $8.92B | +5.67% | 7.02% |
| ASAN | -6.99% | $3.39B | +6.66% | 0.00% |
| ATUS | -6.96% | $1.24B | +40.21% | 0.00% |
| KR | -6.88% | $46.75B | +34.05% | 1.81% |
| XBIT | -6.12% | $90.24M | -55.56% | 0.00% |
| CCEC | -6.12% | $1.02B | +3.91% | 2.48% |
| FCFS | -6.11% | $5.89B | +28.09% | 1.16% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| YEXT | 40.01% | $1.00B | +59.34% | 0.00% |
| PLAY | 39.04% | $1.13B | -16.97% | 0.00% |
| QTTB | 32.84% | $40.50M | -85.20% | 0.00% |
| IBRX | 32.12% | $2.53B | -57.16% | 0.00% |
| GWRE | 30.14% | $18.95B | +64.28% | 0.00% |
| PDSB | 25.85% | $59.42M | -66.49% | 0.00% |
| NOAH | 24.86% | $805.53M | +50.31% | 9.69% |
| RXRX | 24.84% | $2.47B | -25.59% | 0.00% |
| VEEV | 24.81% | $46.02B | +51.44% | 0.00% |
| STM | 24.44% | $29.36B | -20.89% | 1.12% |
| SDGR | 23.83% | $1.59B | +0.70% | 0.00% |
| DYN | 23.82% | $1.25B | -79.03% | 0.00% |
| ENTA | 23.75% | $149.21M | -53.44% | 0.00% |
| FINV | 23.52% | $1.44B | +105.38% | 2.68% |
| FTRE | 23.38% | $476.94M | -78.71% | 0.00% |
| NERV | 23.27% | $11.47M | -51.19% | 0.00% |
| OGI | 23.20% | $196.81M | -13.53% | 0.00% |
| LOAR | 23.15% | $7.36B | +41.85% | 0.00% |
| LEGN | 23.09% | $7.31B | -18.12% | 0.00% |
| IQV | 22.94% | $28.64B | -24.57% | 0.00% |
